PMV Pharmaceuticals (PMVP) Expected to Announce Earnings on Thursday

PMV Pharmaceuticals (NASDAQ:PMVP) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.07. On average, analysts expect PMV Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PMV Pharmaceuticals Stock Down 2.7%

NASDAQ PMVP opened at $1.07 on Thursday. The stock’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.27. PMV Pharmaceuticals has a 52 week low of $1.02 and a 52 week high of $1.88. The company has a market capitalization of $57.06 million, a P/E ratio of -0.72 and a beta of 1.33.

Hedge Funds Weigh In On PMV Pharmaceuticals

Several large investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its position in shares of PMV Pharmaceuticals by 144.3% in the fourth quarter. XTX Topco Ltd now owns 104,485 shares of the company’s stock valued at $131,000 after acquiring an additional 61,723 shares in the last quarter. Tang Capital Management LLC grew its position in shares of PMV Pharmaceuticals by 3.2% during the fourth quarter. Tang Capital Management LLC now owns 4,940,000 shares of the company’s stock worth $6,175,000 after purchasing an additional 154,799 shares in the last quarter. Bridgeway Capital Management LLC raised its stake in PMV Pharmaceuticals by 33.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 428,853 shares of the company’s stock valued at $536,000 after purchasing an additional 108,200 shares during the period. Public Employees Retirement System of Ohio raised its stake in PMV Pharmaceuticals by 349.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock valued at $34,000 after purchasing an additional 21,334 shares during the period. Finally, Squarepoint Ops LLC boosted its stake in PMV Pharmaceuticals by 101.8% in the 4th quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock worth $33,000 after purchasing an additional 13,367 shares during the period. 90.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. LADENBURG THALM/SH SH assumed coverage on PMV Pharmaceuticals in a research note on Wednesday, July 8th. They set a “buy” rating and a $3.00 price objective for the company. Evercore upgraded shares of PMV Pharmaceuticals to a “strong-buy” rating in a research note on Monday, April 13th. Oppenheimer lowered their price target on shares of PMV Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Finally, Weiss Ratings lowered shares of PMV Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.